Role of Flow Cytometric Enumeration of Circulating hMICL ( CD371 ) Positive Leukemic Stem Cells in Diagnosis and Prognostication of BCR :: ABL1 ‐Negative Myeloproliferative Neoplasms
International Journal of Laboratory Hematology · 2026
DOI: 10.1111/ijlh.70128 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2026. Verfasst von Gurleen Oberoi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Flow Cytometry, Myeloproliferative Disorders, Neoplastic Stem Cells, Antigens, CD. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
BCR‐ABL1‐negative myeloproliferative neoplasms (MPNs) often exhibit overlapping clinical and morphological features, making accurate subcategorization challenging. The h‐MICL (CD371) antigen, selectively expressed on leukemic stem cells (LSCs) and absent on CD34 + CD38 − cells in normal or regenerating marrow, represents a potential diagnostic and prognostic marker.
Objectives
This study aimed to evaluate the diagnostic utility of circulating CD34 + CD38 − h‐MICL + cells in subtyping BCR‐ABL1‐negative MPNs and to assess their correlation with the Dynamic International Prognostic Scoring System (DIPSS) score. Additionally, to identify a cut‐off value of CD34 + CD38 − h‐MICL + cells that can effectively differentiate PMF.
Methods
Fifty‐four patients with BCR‐ABL1‐negative MPNs were prospectively enrolled at a tertiary care center in North India over 18 months. Peripheral blood was analyzed via flow cytometry to quantify CD34 + , CD34 + CD38 + , CD34 + CD38 − , and CD34 + CD38 − h‐MICL + cell subsets.
Results
A significant increase in circulating CD34 + CD38 − h‐MICL + cells was observed in patients with overt MF (median 2.8%), prefibrotic MF (4.15%), and post‐PV/ET MF (3%) compared to PV and ET (median 0%; p < 0.001). A threshold of ≥ 0.9% CD34 + CD38 − h‐MICL + cells effectively identified MF cases with 88% sensitivity and 89% specificity. Moreover, a positive correlation was found between the percentage of CD34 + CD38 − h‐MICL + cells and DIPSS score ( ρ = 0.41, p = 0.036), with every 1.72% increase in this cell population corresponding to a 1‐point rise in DIPSS score.
Conclusion
Circulating CD34 + CD38 − h‐MICL + cells represent a promising biomarker; their quantification may aid in subclassification, particularly in distinguishing prefibrotic MF from ET, and may serve as a potential target for future therapeutic strategies. Further validation in larger cohorts is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Gurleen Oberoi, Jasmita Dass, Ganesh Viswanathan, Mukul Agarwal
Zitieren
APA
Oberoi, G., Dhawan, R., Dass, J., Ganju, N., Viswanathan, G., Lata, S., Agarwal, M., Kumar, P. K., Seth, T., Mahapatra, M., & Saxena, R. (2026). Role of Flow Cytometric Enumeration of Circulating hMICL ( CD371 ) Positive Leukemic Stem Cells in Diagnosis and Prognostication of BCR :: ABL1 ‐Negative Myeloproliferative Neoplasms. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.70128
Vancouver
Oberoi G, Dhawan R, Dass J, Ganju N, Viswanathan G, Lata S, et al. Role of Flow Cytometric Enumeration of Circulating hMICL ( CD371 ) Positive Leukemic Stem Cells in Diagnosis and Prognostication of BCR :: ABL1 ‐Negative Myeloproliferative Neoplasms. International Journal of Laboratory Hematology. 2026. doi:10.1111/ijlh.70128
BibTeX
@article{Oberoi2026,
author = {Oberoi, Gurleen and Dhawan, Rishi and Dass, Jasmita and Ganju, Neha and Viswanathan, Ganesh and Lata, Suman and Agarwal, Mukul and Kumar, Pradeep Kumar and Seth, Tulika and Mahapatra, Manoranjan and Saxena, Renu},
title = {Role of Flow Cytometric Enumeration of Circulating hMICL ( CD371 ) Positive Leukemic Stem Cells in Diagnosis and Prognostication of BCR :: ABL1 ‐Negative Myeloproliferative Neoplasms},
journal = {International Journal of Laboratory Hematology},
year = {2026},
doi = {10.1111/ijlh.70128}
}
EUVIMED